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Summary Eighteen patients with advanced cancer have been treated intravenously with human recombinant
tumour necrosis factor (rhTNF). The drug produced febrile reactions at all doses although these were
preventable by steroids and indomethacin. Doses at or above 9 x 105 units (400 pg)m-2 were associated with
hypotension, abnormal liver enzymes, leucopenia and mild renal impairment in a substantial proportion of
patients. RhTNF was cleared from plasma with a half life of -20 minutes but non-linear pharmacokinetics
were seen with decreased clearance at higher doses. In 3 patients, all with lymphoma, improvements in their
tumours were recorded.
RhTNF was noted to produce rapid increases in serum C-reactive protein concentrations. Endogenous
TNF levels were not found to be elevated in 72 cancer patients.
TNF deserves further therapeutic evaluation and these observations support its biological importance as an
endogenous pyrogen, mediator of acute phase protein responses, and a mediator of endotoxic shock.
Tumour Necrosis Factor (TNF) is a protein released by
activated macrophages in response to stimulation by
endotoxin. It was originally described in the serum of mice
treated with Bacillus Calmette-Guerin and bacterial
endotoxin and its characteristic effect in vivo is the
production of necrosis in experimental animal tumours
(Carswell et al., 1975; Matthews & Watkins, 1978;
Matthews, 1978). It has diverse biological effects in other
experimental systems including killing of tumour cells in vitro
(Old, 1985), inhibition of the activity of lipoprotein lipase
(cachectin activity) (Beutler & Cerami, 1987); mediation of
some of the lethal effects of endotoxin in animals (Beutler et
al., 1985), stimulation of granulocytes and fibroblasts (Old,
1985; Beutler & Cerami, 1987; Vilcek et al., 1986), damage
to endothelial cells (Sato et al., 1986), bone resorption
(Bertolini et al., 1986), antiviral activity (Mestan et al., 1986;
Wong & Goeddel, 1986) and cytotoxic effects against
malarial parasites (Taverne et al., 1981,1984). Raised serum
TNF levels are associated with some infections in man
(Scuderi et al., 1986; Waage et al., 1987). Macrophage-
produced TNF (which we have studied) is sometimes
referred to as TNF alph-a to distinguish it from lymphocyto-
toxin, a closely related lymphocyte-product which may be
called TNF beta (Pennica et al., 1984).
The gene for human TNF has now been cloned and
expressed in E. coli making large quantities of human
recombinant TNF (rhTNF) available for experimental and
clinical evaluation (Pennica et al., 1984; Shirai et al., 1985;
Wong et al., 1985; Marmenout et al., 1985). It is a non-
glycosylated protein containing 155 amino acids of relative
molecular weight 17,000 usually arranged in multimeric
form. Initially a propeptide with an additional 76 amino
acids is synthesised and both precursor and mature protein
are about 80% conserved between mouse and man (Old,
1985; Beutler & Cerami, 1987; Pennica et al., 1984; Shirai et
al., 1985; Wong et al., 1985; Marmenout et al., 1985). The
gene in man is located on chromosome 6 (Nedwin et al.,
1985). TNF interacts with high affinity receptors (Rubin et
al., 1985; Kull et al., 1985) although its anti-cancer effect
could be mediated indirectly, in-vivo, perhaps via endothelial
cell damage.
The precise physiological role of TNF and its role in
disease is unclear. A pathophysiological role in cancer
cachexia is possible in man (Beutler & Cerami, 1987) and it
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probably mediates some aspects of endotoxic shock (Beutler
et al., 1985; Waage et al., 1987). TNF is a candidate for the
biological treatment of cancer in view of its well established
activity against experimental cancer. We administered
rhTNF to cancer patients in order to find the maximum
tolerated dose, study its pharmacokinetics and make an
initial evaluation of its anticancer effect. We were also able
to make some observations which may contribute to our
understanding of the biology of TNF in man.
Patients, materials and methods
Study design
New biological materials present special difficulties for early
pharmacological studies. Toxicity is unpredictable and major
species differences between tested species and man are
possible. We adopted a low starting dose and cautious dose
escalation.
Human recombinant TNF is lethal to 10% of mice at a
dose of 9 x 106unitsm-2 i.v. The conventional starting dose
for studies with a new anti-cancer drug with this toxicity in
mice would therefore have been 9 x 105 unitsm-2 (Von Hoff
et al., 1984). We elected to begin treatment at a dose of
9x 103unitsm-2 (3 patients). The study design allowed a
patient to receive 2 treatments at the initial dose separated
by 2 weeks and then one dose escalation for the third dose, 2
weeks later (Table I). Dose levels for escalation were: 9 x 104
unitsm-2 (6pts), 3 x 105 unitsm-2 (6pts), 6 x 105 unitsm-2
(5pts), 9 x 105 unitsm-2 (7pts), 1.2 x 106unitsm-2 (2pts).
Between 3 and 5 patients began treatment at each dose
Table I Study design and patient numbers
No. pts First dose Second dose Third dose
Group 1 3 9x103 9x103 9X 104
Group 2 3 9x 104 9X 104 3 x105
(Ipt withdrawn)
Group 3 4 3 x 105 3 x 105 6x105
(2pts withdrawn)
Group4 3 6x105 6x105 9x105
(Ipt received
6 x 105)
Group 5 5 9x 105 9 X 105 1.2 x105
(2pts withdrawn) (3pts withdrawn)
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level. When 3 patients had adequately tolerated the initial
dose (no more than World Health Organisation grade II
toxicity; WHO, 1979) one escalation in starting dose was
made for the next patient so that most patients received two
different doses. In 5 patients improvement in their disease
was suspected and treatment was continued as long as was
clinically indicated.
Drug administration and observation
Patients were nursed in an intensive care unit with
continuous monitoring of pulse, electrocardiograph and
blood pressure for 24h. Full blood counts, biochemical tests
and urinalysis were repeated 4h after drug administration.
Subsequently, clinical observations, full blood counts,
urinalysis and biochemistry were repeated daily for 7 days in
hospital. As the study progressed, patients were in part
observed daily as outpatients during the 7 days.
Patients
Eighteen patients were treated in the study. Inclusion criteria
were a diagnosis of advanced cancer for which no
conventional treatment existed, informed consent, 18 yrs of
age or over, performance status 2 or less (WHO, 1979),
normal renal, hepatic and respiratory function and a normal
full blood count. In fact, one patient age 17 yrs, one with a
marginally raised serum creatinine (1IjIymol -1) and one
with thrombocytopenia were included. Diagnoses were non-
Hodgkin lymphoma (5), Hodgkin's disease (1) metastatic
malignant melanoma (6), liposarcoma (1), gastrointestinal
cancer (3), lung cancer (2). Eleven were male and 7 female.
Mean age was 41 years (range 17-57); WHO performance
status was 0 in 4 patients, 1 in 4 patients, and 2 in 10
patients. All had previously received conventional cytotoxic
chemotherapy without control of their disease.
TNF
Human recombinant TNF was provided by the Asahi
Chemical Industry Company prepared as previously
described (Shirai et al., 1985). It is highly purified and there
is no evidence of residual bacterial endotoxin. Freeze-dried
TNF was stored at +4°C and reconstituted in sterile water
and then further diluted in 100mls saline, before adminis-
tration over 1 h i.v. The specific activity of the preparation
was 2.2 x 106unitsmg-1. A unit is arbitrarily defined as
the reciprocal of the dilution required to produce 50% cell
survival in-vitro for a sensitive murine cell line (L-M cells).
Different laboratories use different cell strains, and doses in
units may NOT be comparable to ours.
TNF assay
TNF levels in plasma were measured with a two-site enzyme-
linked immunosorbant assay (ELISA) using two different
anti TNF monoclonal antibodies. Briefly, one monoclonal
antibody was immobilised in 96-well microplates. The plates
were washed and test and standard samples were reacted
with this antibody. After further washing, a second
monoclonal antibody conjugated to horseradish peroxidase
was added. This was washed and then substrate added. The
absorbance of the product was measured to estimate TNF
concentration. The assay will detect TNF above a
concentration of 0.1 units m1 (45 pgml 1).
C-reactive protein (CRP)
Serum CRP was measured in 7 patients as an indication of
an acute phase protein response. Sera were stored at -20°C
and CRP assayed using a standard radial immuno-diffusion
technique using antisera and standards obtained from
Behringwerke (AG), Marburg, West Germany. This assay
detects CRP at 10 mg1- 1 and levels above 10 mgI1- are used
by its developers as evidence of an acute phase response
(Cooper & Stone, 1979).
Results
Toxicity
The first 6 patients treated all experienced acute febrile
reactions with moderate or severe rigors which were not
dose-related in severity or incidence. These reactions
represent the unmodified acute biological response to TNF
and are described in some detail. The rigors developed
20min after the beginning of the infusion (median, range 15-
50) and lasted 20min (median, range 15-30). The infusions
were stopped and restarted when the rigors were complete
and no further acute reactions occurred. Fever was noted 1 h
after the beginning of the infusion of TNF, rose to a
maximum at 1.6h and median maximum fever was 38.2°C
(range 37.4-390C). It subsided over 1-4 h and was
monophasic. Tachycardia (median 127min-1) and minor
hypertension (median diastolic increase 10mm Hg) were
associated with the reactions. Maximum tachycardia
occurred in the first 3h (range 0.25-3h) and preceded the
onset of hypotension (see below).
A range of manoeuvres were tried to minimise the acute
reactions using corticosteroids, sedatives, non-steroidal anti-
inflammatory drugs and antihistamines. No treatment
seemed to modify established reactions. Hydrocortisone
and chlorpheniramine pre-treatment were ineffective. Pre-
treatment with i.v. methyl prednisolone (250-500mg) 2h
before TNF and oral indomethacin (50mg) dramatically
reduced the rigors, fevers, tachycardia and hypertension.
Sixteen of 23 patients who received this prophylaxis
experienced no reaction to TNF at all and in the others they
were only mild. The controllable acute febrile reactions were
not considered a dose-limiting toxicity. However, as higher
doses of rhTNF were given several other toxicities were seen:
Hypotension Mild hypotension was seen at doses of TNF
less than 9 xl05um-2 with minimum b.p. 105/60 (median)
and no systolic pressure <80mm Hg and/or diastolic
<55mm Hg. However, at a dose of 9x105um-2, 3/7
patients developed hypotension with diastolic <50mm Hg
and/or systolic <80mm Hg and in one case this was severe
50/35 (from baseline 120/60) and life threatening requiring
i.v. fluids and a dopamine infusion. A fall in blood pressure
(40mm and 20mm of Hg systolic respectively) occurred in
both patients treated at 1.2x 106um-2. Hypotension was
most severe 6-12h after TNF and occurred despite the use
of methyl prednisolone pre-treatment. One patient developed
minimum b.p. of 90/40 after 9x 105um-2 but only 115/55
after 6 x 105 um-2 which also supports the dose relationship
of the hypotension.
Abnormal hepatic enzymes No substantial abnormalities in
LFTs were seen at or below a dose of 3 x 105 um-2. Two of
5 patients who received 6 x 105um-2 and 3 of 7 patients
who received 9 x 105 um-2 developed transient abnormalities
of more than WHO grade II (WHO, 1979) severity in one or
more hepatic enzyme usually alkaline phosphatase. All
returned to pre-treatment levels before the next dose of
TNF. No cummulative abnormalities were noted with
repeated treatments.
Changes in white cell count No changes were seen at doses
of 9 x 103um-2. Between 9x 104 and 6 xl05 unitsm-2 most
patients developed neutrophil leucocytosis of 16-30 x 109 1-1
at 24h returning to normal over a further 24h. At a dose
of 9xl05um-2 profound leucopenia developed in 4 of 7
patients and was less than 1 x 109 leucocytes1-1 in 3
patients. This was very short-lived and white cell counts
returned to normal levels at 24h.
Changes in renal function Elevated creatinine levels to
WHO toxic levels I occurred in 4pts at doses of 9 x I05 and
1.2 x 106 and recovered over 2-3 days. Traces of proteinuria
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and resolved over 1-2 days. No evidence of weight gain or
fluid retention was seen.
The toxicity observations suggest that a dose of
9 x 105 um-2 (400pg) of rhTNF or greater is associated with
a considerable risk of clinically significant hypotension,
hepatic abnormalities and transient leucopenia and should be
regarded as the maximum tolerated dose in man. Each of
these toxicities contributed to the dose limitation.
Anticancer effect
Evidence of possible anticancer effect was seen in three
patients.
1. A 44 year old man with mediastinal diffuse large cell
lymphoma had failed to respond to extensive chemotherapy
and radiotherapy and had extensive solid pleural disease seen
on X-ray and ultrasound. He received rhTNF 9x 104uM-2
twice and then 3 x 105 um-2 once. His disease visible on CXR
regressed but he died of pneumonia and radiation pneumonitis
1 month later. Concomitant medication included high doses of
methylprednisolone and, although he had previously failed to
respond to large doses of corticosteroids, this cannot be
excluded as a factor in the regression of his disease.
2. A 29 year old man with extensive nodular sclerosing
Hodgkin's disease resistant to conventional treatment received
rhTNF 3x105um-2 twice followed by 6x105um-2 on six
occasions as an extension of the study. His severe symptoms
resolved and there was some clearing of lung disease on X-ray.
When rhTNF was stopped, the symptoms recurred after 2
months and then failed to respond to TNF.
3. A 37 year old man with splenic and bone marrow non-
Hodgkin lymphoma resistant to all conventional therapy, had
severe bone marrow failure with life-threatening thrombocyto-
penia (11 x 109-1). A marrow aspirate contained 100%
lymphoma cells. He received rhTNF 9 x 105 um-2 twice,
1.2x 106um-2 once and then prolonged treatment with
6x 105um-2 two weekly. His spleen regressed from 10cm
below costal margin in its long axis to 4cm and his platelet
count has risen to 64 x 109P1 and is presently sustained after
3 months without treatment. His marrow contains 20%
lymphoma cells. He has been receiving low dose prednisolone
without apparent benefit for 6 months before TNF therapy
was given and he continued the steroids during his TNF
treatment.
Although symptomatic improvement occurred in several
other patients, no objective evidence of response was seen.
Acute phase proteins
Serum C-reactive protein concentration was measured before
and 24h after rhTNF (6-9 xlO m-2) in 7 patients. In 3 of
these levels were taken for 2 treatments and in one patient
for 3 treatments. Results are shown in Figure 1. Substantial
a
Iuu -
10 -
I
E
C U-
z
1 -
300 -
J m-2
0.1-
Time (minutes)
0
6 x 105 um-2
3 x 105 um-2
I 1
60 120
Time (minutes)
0-.
I I
Pre
TNF
24 hours
after TNF
Figure 1 C-reactive protein levels before and after rhTNF.
Figure 2 Plasma TNF after intravenous treatment in two
patients. (a) exponential decay at two dose levels but with more
rapid clearance at lower dose; (b) exponential decay at the lower
dose but a convex upward curve at higher dose indicating slower
clearance at high concentrations.
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increases were seen in 6 patients and in each case was seen
with each treatment although the amount of the increase
varied between patients and occasions. Increased CRP was
seen in patients who did not have rigors and was not
prevented by methylprednisolone treatment. One patient
(tested on one occasion only) showed no rise after
6 x 105 um-2 rhTNF despite a moderately severe rigor.
Pharmacokinetics
Pharmacokinetics of rhTNF were studied in 17 patients who
consented to blood sampling within the study and repeated
studies were possible in 11 patients. Samples were taken
through indwelling venous lines before and immediately after
rhTNF infusions and then at 15, 30, 45, 60, 90, 120, 180 and
240min.
The results are shown in Figures 2(a,b) and 3 and in
Table II. No rhTNF was detected in the urine.
In 8 patients, the concentrations of rhTNF fell exponen-
tially on at least one occasion (as shown for 2 patients
in Figure 2) and median half life was 17min (range
8-61 min). In the remaining 9 patients, the plasma decay
curves were not exponential and half lives were not
calculated. In 3 of these 9 patients the data were scattered
and no satisfactory shape to the plasma concentration curves
could be discerned. In 6 patients the curves (log
concentration vs. time) were convex upwards (as illustrated
for one patient in Figure 2b) with less steep slopes at higher
concentrations. In two patients who showed exponential fall
in plasma concentrations on one occasion, convex-upwards
curves were seen on other occasions (Figure 2).
Peak plasma concentrations were read directly from the
curves and areas under the plasma concentration-times
curves were estimated by the trapezoid rule and clearance
calculated from this (Table II). Peak concentration and AUC
increased with dosage. However, clearance of TNF fell with
increasing dose (Figure 3) demonstrating non-linear
pharmacokinetics.
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Figure 3 Calculated clearance of rhTNF at different dose levels
in 17 patients (-mean clerances).
There was considerable variation between patients and
somewhat less between studies in the same patient. These
may be compared at a dosage of 6 x 10 um-2 where most
replication of measurements was possible and the coefficient
of variation (standard deviation/mean %) of AUC between
patients was 45% whereas the average coefficient of
variation of results within one patient was 27%. The
variations between patients could not be explained by sex,
age, diagnosis, organ dysfunction, apparent body fat or
previous TNF administration in this study.
TNF levels in cancerpatients
Endogenous plasma TNF levels were measured in 72
patients untreated with TNF who had malignancy including
51 with lymphoma and 10 with severe cachexia. Samples
were taken, separated and stored at -20°C for several weeks
before being assayed using the two-antibody method. TNF
levels were below the lowest reliable measurements possible
with this assay (0.1 uml-1, 45pgml-1) at the time of
measurement in these cryopreserved samples.
Discussion
This study allows some conclusions to be drawn about
tumour necrosis factor in man. Firstly we can conclude that
the drug can be administered safely to patients in doses up
to 9 x 105unitsm-2 but that at that dose a substantial
proportion of patients develop significant toxicities including
transient leucopenia, hypotension, abnormalities in liver
functions tests and mild renal impairment. The maximum
frequency of administration is not yet known. The febrile
reactions which were seen at all doses can be prevented by
steroids and indomethacin. However, such prophylaxis may
not be desirable because its influence on possible therapeutic
benefits is unknown. Some preliminary observations suggest
it may reduce the anticancer effect in experimental systems
(unpublished). It is notable that the dose at which significant
toxicity was seen would have been a conventional first dose
for a new cytotoxic drug supporting our belief that
additional caution is required in early clinical studies of new
biological treatments.
The lower clearance of TNF seen at higher dosages
together with the convex-upward log concentration-time
curves seen in some patients show that TNF has non-linear
pharmacokinetics. It appears that a clearance mechanism is
saturated by high concentrations but the exact explanation
for the non-linear pharmacokinetics and its biological
significance is unclear. The concentrations of TNF achieved
in the serum are higher than those required to kill some
human cells in tissue culture but are somewhat lower than
those associated with regression of most murine experimental
tumours (Matthews & Watkins 1978; Matthews, 1978 &
unpublished observations).
We are encouraged by the evidence for some regression of
tumours in three patients and further exploration of this
material as a new biological therapy for cancer, seems
justified. The apparent effects on lymphomas may be related
to the known cytotoxic effects of TNF on normal mouse
Table II Pharmacokinetics of rhTNF
Max conc t4 (s.d.) AUC (s.d.) VOD (s.d.) Clearance (s.d.)
Dose uMr2 Pts Studies (s.d.) urn!1 mmin uml- min litres mlmin-I
9x 103 3 3 2.1(2.4) - -
9x104 4 4 4.5(2.7) 10.4(4.6) 364(134) 7.3 (5.0) 457(145)
3x 105 6 6 39.4(22.3) 15.3(4.3) 2326(1794) 4.8 (2) 232(116)
6x 105 5 12 120(50) 21.4(5.4) 9861(4624) 3.6 (1.7) 152(104)
9x 105 4 8 217(101) 26.5(11.7) 24,942(11117) 2.59(0.85) 73(47)
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lymphoid cells (Playfair et al., 1982). However, it must be
emphasised strongly that it is difficult to draw conclusions
about a consistent anticancer effect in man from these
studies and we do not claim on the basis of the available
evidence that this drug has yet been shown to be significant
new treatment.
The occurrence of fevers and rigors after low doses of
TNF suggests that it is an endogenous pyrogen. In rabbits
TNF is pyrogenic directly as well as by the release of
interleukin 1 which results in a biphasic fever (Dinarello et
al., 1986). There is no evidence of biphasic fever in man.
Apart from the production of fever, the toxicity pattern
suggests that TNF may mediate hypotension, abnormal liver
function tests and renal failure in some infectious diseases.
This suggestion is supported by the observation in
experimental animals that anti TNF antibodies reduce
fatalities resulting from experimental infections (Beutler et
al., 1985) and the association of high TNF levels with fatal
meningococcal infection (Waage et al., 1987). It is possible
that the production of TNF may also have a role in the
defence against infections. The activity of the material
against parasites in vitro and the observation that serum
TNF levels are elevated in some parasitic infections (Scuderi
et al., 1986) would support this suggestion.
We have found no evidence of elevation of serum TNF
levels in any patients with malignant disease and this agrees
with some other results (Scuderi et al., 1986). However, we
are using a double-antibody method to measure intact TNF
and have only looked at cryopreserved samples. It is possible
that the production of TNF from peripheral blood
monocytes is increased in cancer patients (Aderka et al.,
1985) and we are exploring this possibility.
A role for TNF in mediation of the acute phase protein
response in animals has already been proposed (Dinarello,
1986). Moreover, there is evidence that TNF may regulate
the expression of hepatic acute phase protein genes in vitro
(Perlmutter et al., 1986). The data presented here suggests
that TNF may indeed mediate the production of some acute
phase proteins in man.
TNF appears to be of considerable biological importance
although its role as a cancer therapy will only become clear
when further studies have evaluated treatment at doses
which we have found to be tolerated and more frequent
administration. The combination of TNF with other
biological agents such as gamma interferon has been shown
in experimental systems to be strongly synergistic (Aggarwal
et al., 1985; Fransen et al., 1986; Balkwill et al., 1987) and
this will justify clinical evaluation of the combination.
Combinations of biological agents with conventional
cytotoxic drugs appear also to be effective in experimental
systems and deserve consideration (unpublished data).
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